Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-R117C · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm A: IMC-R117C Monotherapy Dose-Escalation | EXPERIMENTAL | Participants receive IMC-R117C intravenous (IV) infusion. |
| Arm B: IMC-R117C Combination Dose-Escalation | EXPERIMENTAL | Participants receive IMC-R117C IV infusion in combination with standard of care chemotherapy and antiangiogenic agent |
| Arm C: IMC-R117C Combination Dose-Escalation | EXPERIMENTAL | Participants receive IMC-R117C IV infusion with targeted therapies |
| Arm D: Control Arm | ACTIVE_COMPARATOR | Participants receive standard of care chemotherapy and antiangiogenic agent |
| Name | Type | Description |
|---|---|---|
| IMC-R117C | DRUG | IV infusion |
| Chemotherapy drug | DRUG | IV infusion |
| Kinase inhibitor | DRUG | oral |
| Antiangiogenic Agent | DRUG | IV infusion |
| Monoclonal antibody | DRUG | IV infusion |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * HLA-A\*02:01-positive * Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma * Archived or fresh tumor tissue sample that must be confirmed as adequate * Evaluable...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
IMC-R117C is an investigational small molecule being developed for the treatment of cancer, specifically in patients who are HLA-A*02:01-positive. It is currently being studied in a Phase 1/2 clinical trial for selected advanced cancers. The drug is not yet approved and remains in clinical development.
IMC-R117C targets PIWIL1, a protein involved in cancer biology. By targeting PIWIL1, the drug aims to interfere with cancer cell processes. This mechanism is being evaluated in a Phase 1/2 trial for advanced cancers in HLA-A*02:01-positive patients.
IMC-R117C is being developed by Immunocore Holdings plc, a biopharmaceutical company listed on the stock exchange under the ticker IMCR. The company is conducting a Phase 1/2 clinical trial to evaluate the drug in patients with selected advanced cancers.
IMC-R117C is in Phase 1/2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing trial is recruiting participants with HLA-A*02:01-positive advanced cancers to assess the drug's safety and efficacy.
IMC-R117C is being studied in a Phase 1/2 trial with the identifier NCT06840119, titled 'Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers.' The trial is actively recruiting 600 participants aged 18 years and older in Australia, Belgium, Germany, Italy, Netherlands, and Spain.